- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
How risky is a second allogeneic stem cell transplantation? ; volume:38 ; number:8 ; day:25 ; month:6 ; year:2024 ; pages:1799-1807 ; date:8.2024
Leukemia ; 38, Heft 8 (25.6.2024), 1799-1807, 8.2024
- Urheber
-
Penack, Olaf
Abouqateb, Mouad
Peczynski, Christophe
Boreland, William
Kröger, Nicolaus
Zeiser, Robert
Ciceri, Fabio
Schroeder, Thomas
Dreger, Peter
Passweg, Jakob R.
Schetelig, Johannes
Stelljes, Matthias
Blau, Igor-Wolfgang
Franke, Georg-Nikolaus
Riesner, Katarina
Schoemans, Hélène
Moiseev, Ivan
Peric, Zinaida
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-024-02318-3
- URN
-
urn:nbn:de:101:1-2410132109168.618705886582
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Penack, Olaf
- Abouqateb, Mouad
- Peczynski, Christophe
- Boreland, William
- Kröger, Nicolaus
- Zeiser, Robert
- Ciceri, Fabio
- Schroeder, Thomas
- Dreger, Peter
- Passweg, Jakob R.
- Schetelig, Johannes
- Stelljes, Matthias
- Blau, Igor-Wolfgang
- Franke, Georg-Nikolaus
- Riesner, Katarina
- Schoemans, Hélène
- Moiseev, Ivan
- Peric, Zinaida
- SpringerLink (Online service)
Ähnliche Objekte (12)
Zytomorphometrische Analyse von Speicheldrüsentumoren und verwandter Gewebe : eine computergestützte quantitative Analyse zytologischer Ausstrichpräparate
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
How risky is a second allogeneic stem cell transplantation?
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Optimierung der Mobilisierung von hämatopoetischen Progenitorzellen mit G-CSF bei Patienten mit hämatologischen oder soliden Neoplasien
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
Allogeneic stem cell transplantation for patients age ≥ 70 years with myelodysplastic syndrome: a retrospective study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
Zytomorphometrische Analyse von Speicheldrüsentumoren und verwandter Gewebe : eine computergestützte quantitative Analyse zytologischer Ausstrichpräparate
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
How risky is a second allogeneic stem cell transplantation?
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Optimierung der Mobilisierung von hämatopoetischen Progenitorzellen mit G-CSF bei Patienten mit hämatologischen oder soliden Neoplasien
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
Allogeneic stem cell transplantation for patients age ≥ 70 years with myelodysplastic syndrome: a retrospective study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
Zytomorphometrische Analyse von Speicheldrüsentumoren und verwandter Gewebe : eine computergestützte quantitative Analyse zytologischer Ausstrichpräparate
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
How risky is a second allogeneic stem cell transplantation?
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Optimierung der Mobilisierung von hämatopoetischen Progenitorzellen mit G-CSF bei Patienten mit hämatologischen oder soliden Neoplasien
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
Allogeneic stem cell transplantation for patients age ≥ 70 years with myelodysplastic syndrome: a retrospective study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party